CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
AZD1656 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00856908
NCT00856908Phase 2Completed
CompareCT.gov

A Randomised, Single-Blind, Placebo-Controlled, Phase IIa Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 During Four Weeks in T2DM Subjects Treated With Insulin

AstraZeneca·interventional·Posted Mar 6, 2009·Updated Dec 6, 2012

In Brief

A Phase 2 clinical trial evaluating AZD1656 and Placebo for Type II Diabetes. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The purpose of this study is to assess the 1 month safety and tolerability after multiple oral doses of AZD1656 in patients with Type 2 Diabetes Mellitus Treated with Insulin

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType II Diabetes
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 6, 2009
Enrollment StartFeb 1, 2009
Primary CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 17.3 years ago

Interventions

AZD1656drug

Tolerable dose given twice daily

Placebodrug

Tolerable dose given twice daily